Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-062081
Filing Date
2023-11-09
Accepted
2023-11-09 16:15:37
Documents
57
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q antx-20230930.htm   iXBRL 10-Q 2795601
2 EX-31.1 antx-ex31_1.htm EX-31.1 18146
3 EX-31.2 antx-ex31_2.htm EX-31.2 18560
4 EX-32.1 antx-ex32_1.htm EX-32.1 9279
5 EX-32.2 antx-ex32_2.htm EX-32.2 9080
  Complete submission text file 0000950170-23-062081.txt   8468383

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT antx-20230930.xsd EX-101.SCH 52605
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT antx-20230930_cal.xml EX-101.CAL 34347
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT antx-20230930_def.xml EX-101.DEF 176440
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT antx-20230930_lab.xml EX-101.LAB 416595
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT antx-20230930_pre.xml EX-101.PRE 300213
51 EXTRACTED XBRL INSTANCE DOCUMENT antx-20230930_htm.xml XML 1262511
Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

EIN.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41331 | Film No.: 231392645
SIC: 2834 Pharmaceutical Preparations